Inamura N, Nakahara K, Kino T, Goto T, Aoki H, Yamaguchi I, Kohsaka M, Ochiai T
Exploratory Research Laboratories, Fujisawa Pharmaceutical Company, Ibaraki, Japan.
Transplantation. 1988 Jan;45(1):206-9. doi: 10.1097/00007890-198801000-00042.
FK506, an immunosuppresant, was isolated from Streptomyces tsukubaensis. Intramuscular administration of FK506 (0.32 mg/kg or more) 5 days a week for two weeks after grafting prolonged the acceptance time of F344 skin allograft to WKA rats. Similar results were obtained with cyclosporine at 32 mg/kg or more, but other immunosuppressives (i.e., prednisolone, azathioprine, and bredinin) gave only a marginal prolongation. The prolonging effect of FK506 was obtained in various donor-recipient combinations across a major or minor histocompatibility barrier. The agent also prolonged the acceptance time of mouse skin xenografts to rats. Furthermore, maintenance doses of 3.2 or 0.32 mg/kg twice a week after an initial 14-day treatment with the agent at 3.2 mg/kg gave graft survival as long as the treatment was continued for more than 120 days. Our findings show that FK506 has a potent immunosuppressive effect in rats and suggest that the agent merits further investigation.
免疫抑制剂FK506是从筑波链霉菌中分离得到的。移植后每周5天、连续两周肌肉注射FK506(0.32毫克/千克及以上)可延长F344大鼠皮肤同种异体移植到WKA大鼠的接受时间。32毫克/千克及以上的环孢素也得到了类似结果,但其他免疫抑制剂(即泼尼松龙、硫唑嘌呤和布累迪宁)仅使接受时间略有延长。FK506的延长作用在跨越主要或次要组织相容性屏障的各种供体-受体组合中均有体现。该药物还延长了小鼠皮肤异种移植到大鼠的接受时间。此外,在最初14天以3.2毫克/千克的剂量治疗后,每周两次给予3.2或0.32毫克/千克的维持剂量,只要治疗持续超过120天,移植物就能存活。我们的研究结果表明,FK506在大鼠中具有强大的免疫抑制作用,并表明该药物值得进一步研究。